Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Kenneth F. Grossmann"'
Autor:
Islam Eljilany, Arish Noor, Mahati Paravathaneni, Ibrahim Yassine, Sandra J. Lee, Megan Othus, James Moon, John M. Kirkwood, Vernon K. Sondak, Antoni Ribas, Kenneth F. Grossmann, Ahmad A. Tarhini
Publikováno v:
Cancers; Volume 15; Issue 9; Pages: 2561
Cancers, vol 15, iss 9
Cancers, vol 15, iss 9
Background: Treatment with immune checkpoint inhibitors (ICIs) has been linked to granulomatous and sarcoid-like lesions (GSLs) affecting different organs. This study sought to evaluate GSL incidence in patients with high-risk melanoma treated with c
Autor:
Brian R. Gastman, Ahmad A. Tarhini, Robert M. Conry, Pauline Funchain, Karl D. Lewis, Antoni Ribas, Sapna Pradyuman Patel, Hongli Li, Kenneth F. Grossmann, Magdalena Kovacsovics-Bankowski, Teresa M. Petrella, Elizabeth I. Buchbinder, Nageatte Ibrahim, Ragini R. Kudchadkar, James Moon, Douglas B. Johnson, Thach-Giao Truong, Larissa A. Korde, Michael V. Knopp, Kari Kendra, Elad Sharon, Scot Ebbinghaus, Bartosz Chmielowski, Vernon K. Sondak, John M. Kirkwood, Zeynep Eroglu, Nikhil I. Khushalani, Justine V. Cohen, Megan Othus, Krishna S Gunturu, Sama Ahsan
Publikováno v:
Cancer discovery, vol 12, iss 3
Cancer Discov
Cancer Discov
We conducted a randomized phase III trial to evaluate whether adjuvant pembrolizumab for one year (647 patients) improved recurrence-free survival (RFS) or overall survival (OS) in comparison with high-dose IFNα-2b for one year or ipilimumab for up
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be95c3ea01eedee0bb4c9a85fc5d89b2
https://escholarship.org/uc/item/8x51z8rb
https://escholarship.org/uc/item/8x51z8rb
Autor:
Montaser Shaheen, Jiayi Yu, Charles J. Link, Yousef Zakharia, Ramses F. Sadek, Robert R. McWilliams, Mohammed M. Milhem, Lucinda Tennant, Joseph J. Drabick, Olivier Rixe, Kenneth F. Grossmann, Gabriela R. Rossi, Nicholas N. Vahanian, Erik L. Brincks, Eugene P. Kennedy, Ravindra Kolhe, David H. Munn, Steven S. Shen, Christopher M Smith, Rafal Pacholczyk
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
BackgroundThe indoleamine 2,3-dioxygenase (IDO) pathway is a key counter-regulatory mechanism that, in cancer, is exploited by tumors to evade antitumor immunity. Indoximod is a small-molecule IDO pathway inhibitor that reverses the immunosuppressive
Autor:
Gary C. Doolittle, Thach Giao Truong, Bryan A. Faller, James Moon, Robert M. Conry, Janice M. Mehnert, Adil Daud, Amy K. Harker-Murray, Dennis F. Moore, Michael J. Messino, Alain Algazi, Roger S. Lo, Antoni Ribas, Christopher D. Lao, Kenneth F. Grossmann, Joseph I. Clark, Kari Kendra, Rangaswamy Govindarajan, Luke Dreisbach, Megan Othus
Publikováno v:
Nat Med
Nature medicine, vol 26, iss 10
Nature medicine, vol 26, iss 10
Preclinical modeling suggests that intermittent BRAF inhibitor therapy may delay acquired resistance when blocking oncogenic BRAFV600 in melanoma1,2. We conducted S1320, a randomized, open-label, phase 2 clinical trial (NCT02196181) evaluating whethe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3928f445a7b302bd631e90a1c4fdbe25
https://europepmc.org/articles/PMC8063889/
https://europepmc.org/articles/PMC8063889/
Autor:
Adil Daud, Philip D. Leming, Caroline C. Kim, Siwen Hu-Lieskovan, Menashe Bar-Eli, Elizabeth I. Buchbinder, Sandra J. Lee, Jennifer A. Stein, Richard A. Scolyer, Douglas Grossman, Dekker C. Deacon, Michael A. Marchetti, Jeffrey E. Gershenwald, Elizabeth M. Burton, Nwanneka Okwundu, John M. Kirkwood, Kenneth F. Grossmann, Vernon K. Sondak, Clara Curiel-Lewandrowski, John R. Hyngstrom, Emily Y. Chu, Daniel G. Coit, David Polsky, Marianne Berwick, Sancy A. Leachman, Georgina V. Long, Kari Kendra, Tawnya L. Bowles, John A. Thompson, Elizabeth G. Berry, Joanne M. Jeter, Rebecca I. Hartman, Susan M. Swetter, Megan Othus, Eric A. Smith, Robert L. Judson-Torres, Mitchell S. Stark, Michael E. Ming, Laura K. Ferris, Edmund K. Bartlett, Kelly C. Nelson, Ashfaq A. Marghoob, Julia A. Curtis, John F. Thompson, Suraj S. Venna, Janice M. Mehnert, Maria L. Wei, Larissa A. Korde, David H. Lawson
Publikováno v:
JAMA dermatology, vol 156, iss 9
JAMA Dermatol
JAMA Dermatol
IMPORTANCE: Use of prognostic gene expression profile (GEP) testing in cutaneous melanoma (CM) is rising despite a lack of endorsement as standard of care. OBJECTIVE: To develop guidelines within the national Melanoma Prevention Working Group (MPWG)
Publikováno v:
Ann Transl Med
Immunotherapy has broadened the therapeutic scope and response for many cancer patients with drugs that are generally of higher efficacy and less toxicity than prior therapies. Multiple classes of immunotherapies such as targeted antibodies and immun
Autor:
Justin C. Sowder, Marcus M. Monroe, Luke O. Buchmann, Ying J. Hitchcock, Kenneth F. Grossmann, Shane Lloyd, Jason P. Hunt, Richard B. Cannon
Publikováno v:
Head & Neck. 39:876-880
Background National guidelines support both surgical and radiotherapy (RT) as initial treatment options for early-stage oral cavity squamous cell carcinoma (SCC). There remains limited data evaluating the survival outcomes of RT and the current pract
Autor:
Ammar Sukari, Susan S. Pandya, Kenneth M. Attie, Dawn Wilson, Jade Sun, Kenneth F. Grossmann, Roger B. Cohen, Elizabeta C. Popa, Jared Weiss, Lori J. Wirth, Matthew L. Sherman, Chad E. Glasser, Xiaosha Zhang, Marshall R. Posner, Athanassios Argiris, Nabil F. Saba, Antonio Jimeno
Publikováno v:
Cancer. 122:3641-3649
BACKGROUND Patients with platinum-refractory, recurrent or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN) have limited options. Activin receptor-like kinase 1 (ALK1) is a type I receptor of the transforming growth factor β superf
Autor:
Eleni Tsiroyanni, Merrick I. Ross, Yan Wang, Robert H. Pierce, Lu Gan, Melinda L. Yushak, Kenneth F. Grossmann, Robert H.I. Andtbacka, Katie Niland, Mohammed M. Milhem, Sudha Parasuraman, Jean S. Campbell, Kam Sprott
Publikováno v:
Cancer Research. 78:613-613
Background: The CXCR4/CXCL12 pathway plays a central role in the trafficking of key immune cells in the tumor microenvironment (TME). X4P-001 is an oral, selective, allosteric CXCR4 inhibitor. We hypothesize that the disruption of CXCR4/CXCL12 signal
Autor:
James C. Moon, Michael Wu, Kenneth F. Grossmann, Antoni Ribas, Siwen Hu-Lieskovan, Jeffrey A. Sosman, Danae Campos, Christopher W. Ryan
Publikováno v:
Journal of Clinical Oncology. 36:TPS9603-TPS9603
TPS9603Background: A significant number of patients do not respond to PD-1/L1 blockade because there are no pre-existing tumor antigen-specific T-cells in their tumors ready to attack the cancer. W...